Predict your next investment

Corporation
HEALTHCARE | Medical Facilities & Services
pennmedicine.org

See what CB Insights has to offer

Investments

4

Portfolio Exits

1

Partners & Customers

10

About Penn Medicine

University of Pennsylvania Health System ("Penn Medicine") is a network of healthcare and research facilities.

Penn Medicine Headquarter Location

Philadelphia, Pennsylvania,

United States

800-789-7366

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Penn Medicine Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Penn Medicine Rank

Latest Penn Medicine News

Penn Medicine technology can help physicians detect cancer cells not found in biopsy

May 18, 2022

Naomi Diaz - Wednesday, May 18th, 2022 Technology, combined with an imaging agent, can light up microscopic cancer cells that are typically not visible during biopsy, according to a May 17 study published in Nature Communications . Researchers from the Philadelphia-based Abramson Cancer Center at the University of Pennsylvania combined a cancer-targeted near-infrared tracer with a needle-based confocal laser endomicroscopy system to guide an imaging agent during biopsies, which lit up cancer cells, allowing real-time diagnosis to be completed. With the new technology, malignant or non-malignant tissue biopsies were detected with 96 percent accuracy and made no false negatives on 20 human biopsy specimens. "The emerging ability to light up a single cell that may be invisible to the eye provides great opportunity to give patients the best chance at an early diagnosis before cancer spreads," said Gregory Kennedy, MD, a resident in general surgery at Penn Medicine. "This unique approach has the potential to improve the information we get from biopsies and it may increase our chances of identifying cancer early." The researchers hope this approach can be used to help with earlier diagnosis of other cancer types, as current medical technology does not provide real-time diagnostic information during biopsy.

Penn Medicine Investments

4 Investments

Penn Medicine has made 4 investments. Their latest investment was in Interius BioTherapeutics as part of their Series A on May 5, 2021.

CBI Logo

Penn Medicine Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/18/2021

Series A

Interius BioTherapeutics

$76M

Yes

14

3/1/2021

Series B - II

Subscribe to see more

$99M

Subscribe to see more

10

6/27/2018

Series A

Subscribe to see more

$99M

Subscribe to see more

10

1/16/2018

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/18/2021

3/1/2021

6/27/2018

1/16/2018

Round

Series A

Series B - II

Series A

Series A

Company

Interius BioTherapeutics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$76M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

14

10

10

10

Penn Medicine Portfolio Exits

1 Portfolio Exit

Penn Medicine has 1 portfolio exit. Their latest portfolio exit was Tissue Analytics on May 14, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

5/14/2020

Acquired

1

Date

5/14/2020

Exit

Acquired

Companies

Valuation

Acquirer

Sources

1

Penn Medicine Acquisitions

2 Acquisitions

Penn Medicine acquired 2 companies. Their latest acquisition was Lancaster Neuroscience & Spine Associates on January 03, 2019.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

1/3/2019

$99M

Acquired

1

1/9/2018

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/3/2019

1/9/2018

Investment Stage

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

Note

Acquired

Subscribe to see more

Sources

1

10

Penn Medicine Partners & Customers

10 Partners and customers

Penn Medicine has 10 strategic partners and customers. Penn Medicine recently partnered with Evergreen Nephrology on March 3, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

3/11/2022

Partner

United States

Penn Medicine forms joint venture with Evergreen Nephrology to transform care for kidney disease patients

Effective January 1 , 2022 , the joint venture -- a 50/50 partnership between UPHS and Evergreen -- contracts with the Centers for Medicare and Medicaid Services to provide care for Medicare patients with kidney disease , including those receiving dialysis .

2

1/1/2022

Partner

United States

First-of-its-Kind Value-Based Care Model Aimed at Improving Outcomes While Containing Costs of Care. Penn Medicine Forms Joint Venture with Evergreen Nephrology to Transform Care for Kidney Disease Patients - Penn Medicine

Effective January 1 , 2022 , the joint venture -- a 50/50 partnership between UPHS and Evergreen Nephrology -- contracts with the Centers for Medicare and Medicaid Services to provide care for Medicare patients with kidney disease , including those receiving dialysis .

1

11/29/2021

Partner

United States

1

9/23/2021

Partner

United States

Subscribe to see more

Subscribe to see more

10

5/11/2021

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

3/11/2022

1/1/2022

11/29/2021

9/23/2021

5/11/2021

Type

Partner

Partner

Partner

Partner

Partner

Business Partner

Country

United States

United States

United States

United States

United States

News Snippet

Penn Medicine forms joint venture with Evergreen Nephrology to transform care for kidney disease patients

Effective January 1 , 2022 , the joint venture -- a 50/50 partnership between UPHS and Evergreen -- contracts with the Centers for Medicare and Medicaid Services to provide care for Medicare patients with kidney disease , including those receiving dialysis .

First-of-its-Kind Value-Based Care Model Aimed at Improving Outcomes While Containing Costs of Care. Penn Medicine Forms Joint Venture with Evergreen Nephrology to Transform Care for Kidney Disease Patients - Penn Medicine

Effective January 1 , 2022 , the joint venture -- a 50/50 partnership between UPHS and Evergreen Nephrology -- contracts with the Centers for Medicare and Medicaid Services to provide care for Medicare patients with kidney disease , including those receiving dialysis .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

1

1

10

10

Penn Medicine Team

19 Team Members

Penn Medicine has 19 team members, including current Chief Executive Officer, Theresa Larivee.

Name

Work History

Title

Status

Theresa Larivee

Chief Executive Officer

Current

Meredith Fox

Chief Financial Officer

Current

Julia Puchtler

Chief Financial Officer

Current

Lu Ann Brady

Chief Operating Officer

Current

Thomas Gakis

Chief Operating Officer

Current

Name

Theresa Larivee

Meredith Fox

Julia Puchtler

Lu Ann Brady

Thomas Gakis

Work History

Title

Chief Executive Officer

Chief Financial Officer

Chief Financial Officer

Chief Operating Officer

Chief Operating Officer

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.